The NFL Players Association and NFL are launching a measure to understand the potential of marijuana and its by-products, such as CBD, as an optional pain treatment.
The two bodies are focused on exploring how marijuana use impacts athletic performance.
An inquiry for information that was launched on Tuesday asserts that the league’s objective is to ascertain investigators who can conduct studies concentrated at complementing the NFLPA-NFL Pain Management Commission’s insight into athletic performance and pain management among NFL athletes.
The notice highlights three focus areas;
- The therapeutic responsibility of drugs and non-clinical interventions that’re regarded as opioid alternatives in NFL players’ pain management. Medications can include cannabinoids,
- The effect of cannabinoids or marijuana on NFL player’s athletic performance.
- The therapeutic potential role of non-medical interventions and medications that’re regarded adjunctive to regular orthopedic post-surgical pain management in NFL athletes
Last year, the joint NFLPA-NFL also noted that it stalled two educative CBD forums to discern the current status-quo of CBD manufacturing and science within North America.
The results of those fora were not definitive while non-intoxicating CBD shows potential in treating some pain varieties.
The Committee wrote in the player’s white paper that cannabidiol is a promising organic compound; however, the amount of its use outruns the amount of research at that juncture. It added that most of the excitement around CBD is centered around findings from animal tests.
This recent inquiry of information underscores that the National Football League is not allocating any funds for any study. It’s intended to assist the league in finding eligible scientists in case it moves ahead with research studies on these concerns. Interested entities have up to 31st March to file relevant details.
This measure comes after NFL’s drug testing reform was adjusted in 2020 as a component of a collective bargaining contract.
